{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:13:38Z","timestamp":1757628818066,"version":"3.44.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Small cell lung cancer (SCLC) accounts for approximately 15% of lung tumors and is marked by aggressive growth and early metastatic spread. In this study, we used two SCLC mouse models with differing tumor mutation burdens (TMB). To investigate tumor composition, spatial architecture, and interactions with the surrounding microenvironment, we acquired multiplexed images of mouse lung tumors using imaging mass cytometry (IMC). These data build upon a previously published characterization of the mouse model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Data description<\/jats:title>\n            <jats:p>After tumor detection, mice were assigned to one of five treatment groups. Lung tumor tissues were imaged with a 37-marker IMC panel designed to identify major cell types\u2014tumor, immune, and structural\u2014as well as their functional states. When possible, each tumor was sampled both at its center and border regions. Tumor masks in the form of binary images are provided to delineate tumor areas. Additional metadata include tumor onset and endpoint dates to support downstream correlation or predictive analyses based on the image data. This dataset offers a valuable resource for studying the histological and cellular complexity of SCLC in a genetically controlled mouse model across multiple therapeutic conditions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13104-025-07460-4","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:04:36Z","timestamp":1757343876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Imaging mass cytometry dataset of small-cell lung cancer tumors and tumor microenvironments"],"prefix":"10.1186","volume":"18","author":[{"given":"France","family":"Rose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olta","family":"Ibruli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Lichius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Kiljan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokcen","family":"Gozum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoela Iannicelli","family":"Caiaffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-na","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan M.","family":"Herter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Gr\u00fcll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Beleggia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziella","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grit S.","family":"Herter-Sprie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Bozek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"issue":"3","key":"7460_CR1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jtho.2015.10.008","volume":"11","author":"AG Nicholson","year":"2016","unstructured":"Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WEE, Van Meerbeeck J, Rami-Porta R. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the Tnm classification for lung cancer. J Thorac Oncol. 2016;11(3):300\u201311.","journal-title":"J Thorac Oncol"},{"key":"7460_CR2","doi-asserted-by":"publisher","unstructured":"Rudin CM, Brambilla E, Corinne Faivre-Finn, and Julien Sage. Small-Cell lung cancer. Nat Reviews Disease Primers. 2021;7(1). https:\/\/doi.org\/10.1038\/s41572-020-00235-0.","DOI":"10.1038\/s41572-020-00235-0"},{"key":"7460_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.tig.2014.06.003","volume":"30","author":"F Dietlein","year":"2014","unstructured":"Dietlein F, Thelen L, Reinhardt HC. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 2014 a;30:326\u201339. (Elsevier Ltd.).","journal-title":"Trends Genet"},{"issue":"1","key":"7460_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","volume":"187","author":"Q Liu","year":"2024","unstructured":"Liu Q, Zhang J, Guo C, Wang M, Wang C, Yan Y, Sun L, Wang D, Zhang L, Yu H, Hou L, Wu C, Zhu Y, Jiang G, Zhu H, Zhou Y, Fang S, Zhang T, Hu L, Zhang P. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell. 2024;187(1):184\u2013e20328.","journal-title":"Cell"},{"key":"7460_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00432-024-05942-9","volume":"150","author":"O Ibruli","year":"2024","unstructured":"Ibruli O, Rose F, Beleggia F, Schmitt A, Cartolano M, Torres Fernandez L, Saggau J, Bonasera D, Kiljan M, Gozum G, Lichius L, Niu L, Iannicelli Caiaffa M, Herter JM, Walczak H, Liccardi G, Gr\u00fcll H, B\u00fcttner R, Bosco G, George J, Thomas RK, Bozek K, Reinhardt HC, Herter-Sprie GS. A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint Blockade. J Cancer Res Clin Oncol. 2024;150:496. https:\/\/doi.org\/10.1007\/s00432-024-05942-9.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7460_CR6","doi-asserted-by":"publisher","unstructured":"Image data are available in the Image Data Resource. (https:\/\/idr.openmicroscopy.org) under accession number idr0170. https:\/\/doi.org\/10.17867\/10000208","DOI":"10.17867\/10000208"},{"issue":"7563","key":"7460_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George J, Lim JS, Jang SJ, Cun Y, Ozretia L, Kong G, Leenders F, Lu X, Fern\u00e1ndez-Cuesta L, Bosco G, M\u00fcller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Thomas RK. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47\u201353. https:\/\/doi.org\/10.1038\/nature14664.","journal-title":"Nature"},{"issue":"8005","key":"7460_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41586-024-07177-7","volume":"627","author":"J George","year":"2024","unstructured":"George J, Maas L, Abedpour N, Cartolano M, Kaiser L, Fischer RN, Scheel AH, Weber JP, Hellmich M, Bosco G, Volz C, Mueller C, Dahmen I, John F, Alves CP, Werr L, Panse JP, Kirschner M, Engel-Riedel W, et al. Evolutionary trajectories of small cell lung cancer under therapy. Nature. 2024;627(8005):880\u20139. https:\/\/doi.org\/10.1038\/s41586-024-07177-7.","journal-title":"Nature"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07460-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-025-07460-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07460-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:07:39Z","timestamp":1757498859000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-025-07460-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7460"],"URL":"https:\/\/doi.org\/10.1186\/s13104-025-07460-4","relation":{},"ISSN":["1756-0500"],"issn-type":[{"type":"electronic","value":"1756-0500"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments in this study were approved by the local Ethics Committee of Animal Experiments authorities (LANUV, North Rhine-Westphalia, Germany) under license number 81-02.04.2019-A491. All mice were maintained according to FELASA recommendations and in compliance with the European Union and German guidelines. Mice were monitored biweekly for tumor progression using MRI imaging, and animals were euthanized once a sufficient tumor burden was reached, as per predefined criteria (e.g., weight loss\u2009>\u200920%, severe tumor ulceration, or breathing difficulties). Euthanasia was conducted in compliance with the license 8102.04.2019-A491 approved by the LANUV authority (North-Rhine-Westphalia, Germany) and adhered to FELASA, EU, and German guidelines. The euthanasia method involved terminal anesthesia followed by transcardial perfusion with 10 ml sterile PBS to clear blood from the lungs and minimize contamination of tissue samples. The specific anesthesia used for imaging and terminal procedures was isoflurane (2.5% in oxygen) or intraperitoneal injection of ketamine (100 mg\/kg) combined with xylazine (20 mg\/kg). Anesthesia depth was confirmed by the absence of response to toe pinch before proceeding with perfusion and tissue harvesting. This approach was chosen to ensure minimal suffering, rapid unconsciousness, and high-quality tissue preservation suitable for downstream analyses such as IMC and genomic studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval ans consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.C.R. received consulting and lecture fees from Abbvie, AstraZeneca, Vertex, and Merck. H.C.R. received research funding from AstraZeneca and Gilead Pharmaceuticals. H.C.R. is a co-founder of CDL Therapeutics GmbH. The remaining authors declare no competing financial interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"385"}}